Tokyo, Japan – June 30, 2025 – Neusignal Therapeutics, Inc., a Tokyo-based company focused on commercializing early-stage drug discovery from Tohoku University, today announced the appointment of Itaru Arimoto, Ph.D. as its Representative Director and CEO, effective June 30, 2025. Dr. Arimoto, previously the Executive Chief Development Officer, takes over from Yoshifumi Yoshida, who retires as Representative Director and CEO today upon the completion of his term.

Under its new leadership, Neusignal Therapeutics will continue advancing the development of its existing pipeline. The company is committed to pioneering groundbreaking treatments for Alzheimer’s disease, an escalating health challenge worldwide, and improving the lives of patients and their families.

Company overview
Established: April 2022
Location: 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan
Representative Director: Itaru Arimoto, Ph.D.
Business activities: Research and development of treatments for dementia and psychiatric disorders, exploration of early-stage drug discovery for brain diseases.
Website: https://neusignal-tx.com/